Angesichts des Drucks der Trump-Regierung hat der Schweizer Pharmariese Roche seine seit langem bestehenden globalen ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in ...

UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and ...

Swiss pharmaceutical giant Roche is cutting its global diversity workforce targets, aligning with recent U.S. legal changes ...

Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...

An experimental drug appears to reduce the risk of Alzheimer’s-related dementia in people destined to develop the disease in ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

Shamrock Rovers hold a three-point advantage at the summit of the Premier Division after overcoming local rivals Moyne ...

The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.

New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ...

Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...